辉瑞以史上最大 ADC 并购案——430 亿美元收购 Seagen 后，艾伯维 101 亿、强生 20 亿、罗氏 10 亿，各家纷纷押注 ADC 赛道。今年依然热度不减，大冢制药 11 亿买入，罗氏再度加码 ADC 斥资 10 亿美元牵手 ...

Orum said recently that preclinical results with ORM-6151 suggest it should offer better tolerability than Pfizer’s Mylotarg (gemtuzumab ozogamicin), a CD33-targeting ADC that has been approved ...

Pfizer’s Mylotarg is back on the US market after a ... acute myeloid leukaemia patients whose tumours express the CD33 antigen, and adults and children two years and older with relapsed or ...

located in 49 states and containing approximately 47.2 million square feet of gross leasable area. The Company's common stock is listed on the New York Stock Exchange under the symbol "ADC".

过去辉瑞CD33 ADC产品Mylotarg（简称GO）曾在美国获批，因肝毒性问题撤市，后通过降低剂量的大样本临床数据获得FD批准治疗CD33+新确诊和复发/难治AML ...

So far, only one drug has been approved by the FDA: gemtuzumab ozogamicin (Mylotarg; Pfizer), a humanized mAb specific for CD33, conjugated ... is now the latest-stage ADC among a total of six ...

ADC什么时候火起来的？ ADC的故事，要追溯到2000年。这一年，惠氏制药（现属辉瑞）研发的Mylotarg作为全球首款ADC药物获批，用于治疗CD33阳性急性髓系白血病。但因3期临床中出现致死性毒性在2010年黯然退市。 此后，ADC领域陷入了漫长的沉寂期。在2010-2018这八 ...

No other corporate actions details are available.

At the same time, CRISPR-Cas9 technology can be used to perform gene ablation on CD33 antigen to kill AML cells. Telomerase is considered to be an important target in the study of cancer vaccine ...